WORKING PAPERS

  • Financial Shocks, Intangible Reallocation, and Innovation, (with Tianyuan Jiang, Xuan Tian, and Xuan Zhang), August. 2026. 
  • Contracting on Price, Compensating on Quality: Evidence from Centralized Drug Procurement, (with Jiang Bin, Qingyuan Xue, Jiayu Zhang, and Xuan Zhang), August, 2026. 
  • Centralized Drug Procurement, Utilization Gains, and Equitable Access: Evidence from China’s National Rollout, (with Bin Jiang, Qingyuan Xue, Jiayu Zhang, and Xuan Zhang), August, 2026.​ R&R at Journal of Health Economics. 
  • Market Definition for Zero-Price Multi-Sided Platforms: A Critical-Loss SSNDQ Test and Evidence from China's Merger Case, (with Jiong Gong, Yumin Li, and Yanhua Zhang), July 2026.​ Under review.​
  • 集采药企的省份供应决策及对药品可负担性的影响——基于新结构经济学视角的研究，（合作者：邓舒心，薛清元，刘凡瑜），2026年8月。​
  • ​​Venture Capital and Knowledge Transfer, (with Roberta Dessi, Sanxi Li), June 2019.

WORK IN PROGRESS  

  • How Does NRDL Negotiation Promote the Use of High-Value Innovative Medicines? Evidence from Hospital Procurement Data, (with Bin Jiang, Chuhao Ji, Peixiong Lin, Fanyu Liu), Dec. 2025.
  • The Impact of NRDL Negotiation on Innovation: Evidence from Listed Pharmaceutical Firms, (with Fanyu Liu, Qi Zhu), Dec. 2025.
  • The Impact of the Double Reduction Policy on Children's Mental Disorders: Evidence from Hospital Procurement Data and CFPS, (with Heng Chen, Yongqi Li, Qingyuan Xue, Xuan Zhang), Dec. 2025. ​​

PUBLICATIONS  

  1. ​​Has the Shortened Drug Distribution Chain Cut Drug Prices? Evidence from the Two-Invoice System in China (with Xiaoxi Li, Fanyu Liu and Jianye Yan),  Journal of Health Economics, Volume 105, January 2026, 103097. 
  2. Impact of Antitrust Events on Firm Market Value: Evidence from Chinese and U.S. Internet Platforms, (with Yong Huang, Yanhua Zhang and Shan Zhao),  Review of Industrial Organization, 67, 251–288, 2025.
  3. Pharmaceuticals, Incremental Innovation and Market Exclusivity,  International Journal of Industrial Organization, Volume 87, March 2023. ("The IJIO Best Empirical Paper 2023")
  4. New Clinical Information and Physician Prescribing: How Do Pediatric Labeling Changes Affect Prescribing to Children? (with Mary K. Olson),  Health Economics, 30(1): 144-164, January 2021. 
  5. Economic Analysis Under the Anti-Unfair Competition Law in China: Tencent v. Xinhui, (with Vanessa Yanhua Zhang and John Jiong Gong), CPI Antitrust Chronicle, March 2019.​
  6. Multitask Assignments with Adverse Selection, (with Minbo Xu, Sanxi Li), Economics Letters,  181:127-132, August 2019.
  7. Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity (with Mary K. Olson), American Journal of Health Economics 4(3): 321-357, Summer 2018. 
  8. The Impact of Venture Capital on Innovation, (with Roberta Dessi), in D. Cumming, ed. The Oxford Handbook of Venture Capital, Oxford University Press, Chapter 22, 2012. 
  9. Socio-economic Status and Chronic Diseases: The Case of Hypertension in China (with Xiaoyan Lei, Yaohui Zhao), China Economic Review, 23 (2012) 105-121. 
  10. 双边市场中的排他性交易与补贴：平台竞争与社会福利分析, (合作者：李瑜敏，巩晓劼)，《世界经济文汇》，2024, 01(04): 1-24。
  11. 非正规金融的运行——社会网络的作用, (合作者：尹训东), 《世界经济文汇》, 2017, 1(01),51-68.